Lymphoma / Leukemia / Myeloma News From Medical News Today
Diet-Induced Obesity Accelerates Leukemia
09:00:00 CEST +0200 September 9th, 2010
The first study to demonstrate that obesity can directly accelerate the progression of acute lymphoblastic leukemia (ALL) has been conducted at The Saban Research Institute of Childrens Hospital Los Angeles and will be published in Cancer Prevention Research, on October 5, 2010...
Promising New Lymphoma Treatment Effective In Dogs
14:00:00 CEST +0200 September 8th, 2010
Researchers have identified a new target for the treatment of lymphoma and are testing a potential new drug in pet dogs afflicted with the disease. At low doses, the compound, called S-PAC-1, arrested the growth of tumors in three of six dogs tested and induced partial remission in a fourth...
TenX Biopharma Reinitiates Enrollment In Pivotal Phase III, CTCL Trial
12:00:00 CEST +0200 September 8th, 2010
TenX Biopharma, Inc. announced that it has re-initiated enrollment in the pivotal Phase III clinical trial assessing zanolimumab treatment for cutaneous T-cell lymphoma (CTCL) patients. The trial enrollment was suspended in October 2008 while Genmab (CO:GEN) was seeking a out-license agreement to further develop the compound...
St. Jude Researcher Receives Grant To Focus On Cancer Pharmacogenomics In Children
10:00:00 CEST +0200 September 8th, 2010
With its new expansion of the Pharmacogenomics Research Network (PGRN), the National Institutes of Health (NIH) awarded St. Jude Children's Research Hospital a prestigious grant to focus on anticancer agent research in children. The five-year, $8.6 million grant is titled "PAAR4Kids Pharmacogenomics of Anticancer Agents Research in Children." "We've been part of the PGRN for 10 years...
The Capacity Of 4-HPR To Induce Death Of Tumour Cells, Applying It To Acute Lymphoblastic Leukaemia
09:00:00 CEST +0200 September 8th, 2010
Retinoic acid (RA), a natural derivative of vitamin A, is the basis of a number of treatments against cancer. Nevertheless, it has certain disadvantages, such as the possibility of the appearance of retinoic acid syndrome, present in 25% of cases and which can lead to death...
Celgene Officially Notified Of ANDA Filing For REVLIMID(R)
13:00:00 CEST +0200 September 6th, 2010
Celgene Corporation (NASDAQ: CELG) announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA)...
Acupuncture Helps Ease Side Effects And Symptoms Of Some Cancers
09:00:00 CEST +0200 September 5th, 2010
Recent studies have shown that acupuncture can help control a number of symptoms and side effects -- such as pain, fatigue, dry mouth, nausea, and vomiting -- associated with a variety of cancers and their treatments...
Blood Publication Shows MLN4924 Preclinical Activity In Lymphoma
09:00:00 CEST +0200 September 5th, 2010
Millennium: The Takeda Oncology Company announced the publication of an article in the journal Blood describing the novel mechanism of action of MLN4924 through targeted pathway modulation in diffuse large B-cell lymphoma (DLBCL). MLN4924 is a small molecule inhibitor of the NEDD8-Activating Enzyme (NAE), a key component of the protein homeostasis pathway...
Molecular Imaging's Benefits In The Evaluation And Successful Treatment Planning For A Wide Spectrum Of Diseases
10:00:00 CEST +0200 September 3rd, 2010
A series of studies published in the September Journal of Nuclear Medicine (JNM) show that molecular imaging plays a critical role in the evaluation and treatment planning for a broad spectrum of cancers, including thyroid cancer and lymphoma...
Novartis Drug TasignaŽ Approved In Switzerland After Fast-track Review For Treatment Of Patients With Newly Diagnosed Ph+ CML
12:00:00 CEST +0200 September 2nd, 2010
The Swiss health authority Swissmedic has granted approval for TasignaŽ (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase...
Taking Aim At Pre-Leukemia Disorders: NewYork-Presbyterian/Columbia Establishes Myelodysplastic Syndromes Center
10:00:00 CEST +0200 August 31st, 2010
NewYork-Presbyterian Hospital/Columbia University Medical Center has established a new center devoted to research and treatment of pre-leukemia blood disorders. Known as the Myelodysplastic Syndromes Center, it is one of the largest programs of its kind in the nation. Myelodysplastic syndromes (MDS) are disorders interfering with blood production in the bone marrow...
LFB's Recombinant Anti-CD20 Monoclonal Antibody Is Granted Orphan Drug Status In The USA For Chronic Lymphocytic Leukemia
10:00:00 CEST +0200 August 27th, 2010
The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orphan Products Development was granted on August 6th, 2010. Chronic lymphocytic leukemia is the most common form of leukemia in the United States...
NICE Proposes To Restrict Access To Velcade(R) In Newly Diagnosed Multiple Myeloma Patients Janssen-Cilag To Challenge NICE Recommendation
10:00:00 CEST +0200 August 27th, 2010
Janssen-Cilag is disappointed that recommendations from the National Institute for Health and Clinical Excellence (NICE) will limit patient access to Velcade (bortezomib) in newly diagnosed (front-line) multiple myeloma...
NICE Draft Guidance Recommends Bortezomib And Thalidomide For Multiple Myeloma
15:00:00 CEST +0200 August 26th, 2010
In draft guidance published today (26 August 2010) NICE has recommended two treatments for multiple myeloma. Thalidomide (Thalidomide, Celgene) in combination with an alkylating agent and a corticosteroid is recommended for the first-line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate...
CAS Chemistry Research Report, A Decade Later Human Genome Discoveries Spur Growth Of Cancer Treatments
11:00:00 CEST +0200 August 25th, 2010
Today, leukemia patients who have struggled with cancer therapy resistance and intolerance will now have more options thanks to targeted drug therapy. Such new treatment options are due, in part, to a rapid increase in journal and patent publications following the discovery of Gleevec, as reported by Chemical Abstracts Service (CAS), the world's authority for chemical information...
Extensive Trial Confirms Benefits Of Early Steroid Withdrawal For Transplant Patients
09:00:00 CEST +0200 August 25th, 2010
A University of Cincinnati (UC) analysis of 10 years of data from local kidney transplant patients shows that patients removed from a corticosteroid regimen shortly after surgery have better graft survival rates, better survival rates and fewer cardiovascular events than patients kept on the traditional regimen of long-term steroids...
EpiCept Corporation Receives Refusal To File Letter From US FDA On Ceplene New Drug Application
09:00:00 CEST +0200 August 24th, 2010
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) announced that it received a refusal to file letter from the U.S. Food and Drug Administration (FDA) on the New Drug Application (NDA) for CepleneŽ (histamine dihydrochloride)...
Lawrence Medical Products Launches MoveAround? IV Buggy For Kids - Toddler Age To Teen - Undergoing IV Therapy
10:00:00 CEST +0200 August 19th, 2010
Lawrence Medical Products, a family-owned business conceived to help Autumn Lawrence, diagnosed with infant leukemia in 2005 at seven and a half months old, has announced the launch of the MoveAround? IV Buggy...
Link Between Blood Stem Cell And Leukemia Illuminated In UCSF-Led Study
09:00:00 CEST +0200 August 18th, 2010
A UCSF-led team has discovered at least one key reason why blood stem cells are susceptible to developing the genetic mutations that can lead to adult leukemia. Their finding also may explain, they say, why some other age-related hematological disorders develop...
EMEA Validates Cell Therapeutics, Inc.'s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
11:00:00 CEST +0200 August 17th, 2010
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that it has received notice that the European Medicines Agency ("EMEA") has validated the expanded Pediatric Investigation Plan ("PIP") that CTI filed in July for pixantrone for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL)...
Mesoblast Limited (ASX:MSB) On Track For Phase 3 Bone Marrow Transplant Trial Following Positive Meeting With United States FDA
11:00:00 CEST +0200 August 16th, 2010
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today provided market guidance on its Phase 3 bone! marrow transplant program following a formal meeting with the! United States Food and Drug Administration (FDA)...
Technique To Preserve Fertility In Young Women May Be Unsafe For Patients With Leukemia
10:00:00 CEST +0200 August 14th, 2010
Although the use of ovarian tissue cryopreservation and transplantation has lead to 13 live births in women with lymphoma or solid tumors, this method of fertility preservation may be unsafe for patients with leukemia, according to a recent study published online in Blood, the journal of the American Society of Hematology...
Understanding How Blood Stem Cells Are Maintained Within The Niche Offers New Opportunities To Exploit Them Therapeutically
09:00:00 CEST +0200 August 14th, 2010
Hematopoietic stem cells (HSCs) have two unique abilities that are prized by medical researchers: to self-renew and to develop into any kind of blood cell, which enables them to replenish the entire blood and immune system...
Genmab Announces Top-Line Interim Results For Ofatumumab In Diffuse Large B-Cell Lymphoma
11:00:00 CEST +0200 August 11th, 2010
Genmab A/S (OMX: GEN) announced today top-line interim results from an initial Phase II single arm open label study of ofatumumab to evaluate the treatment of relapsed Diffuse Large B-Cell Lymphoma (DLBCL) in patients ineligible for or relapsed following a stem cell transplant...
Familial Link In Rare Childhood Leukemia
11:00:00 CEST +0200 August 10th, 2010
A UCSF-led team has discovered a direct link between an inherited genetic mutation, a set of developmental abnormalities and a rare form of childhood leukemia called juvenile myelomonocytic leukemia, or JMML. The study demonstrates a new familial link in JMML and has significant implications, the researchers say, for improving the diagnosis and treatment of the disease...
